Skip to main content
. 2006 Feb 20;147(8):959–965. doi: 10.1038/sj.bjp.0706691

Figure 2.

Figure 2

RIST after SIN-1 as a function of the dose of GSH-E administered intravenously, n=12 or intraportally, n=23. Insulin sensitivity is dependent on the dose of GSH-E. GSH-E is more potent and more efficient when administered intraportally than systemically.